PETER ROST: PHARMA MARKETING EXPERT WITNESS. AWP, MEDICAL DEVICE EXPERT.: Only for women in Europe.
screen2largeMM

Dr. Rost provides services as a pharmaceutical marketing expert witness. For more info see: Drug Expert Witness. Dr. Peter Rost email. Copyright © 2006-2013 InSync Communication. All rights reserved. Terms of use agreement, privacy policy and the computer fraud and abuse act.
.

PETER ROST: PHARMA MARKETING EXPERT WITNESS. AWP, MEDICAL DEVICE EXPERT.

Peter Rost, M.D., is a former Pfizer Marketing Vice President providing services as a medical device and drug expert witness and pharmaceutical marketing expert. Judge Sanders: "The court agrees with defendants' view that Dr. Rost is a very adept and seasoned expert witness." He is also the author of Emergency Surgery, The Whistleblower and Killer Drug. You can reach him on rostpeter (insert symbol) hotmail.com. Please read the terms of use agreement and privacy policy for this blog carefully.

Only for women in Europe.

A new sex drug, used as a body patch, and claiming to improve women's libido, is among 20 (!) female sex drugs that are hitting the market in the U.K. this week.

Trials have shown that the hormone-based patch, Intrinsa, helps women both think about sex and want it more often. It works by releasing the male hormone testosterone into the bloodstream.

More from the Telegraph.

The availability of the patch is likely to increase the following situations:

Everyeone remembers Meg Ryan and "I'll have what she's having."



Here's the German version, from "Mädchen Mädchen."



Oh, one more thing . . . the lady in the car? She says: "Next time we'll take our bikes."

Finally, Love Island's Sophie does a Meg Ryan without actually using Intrinsa.



Warning: These are all actors, they are not enjoying themselves. Only Intrinsa can do that for you, taken together with a good man.

And you can only get this drug in the UK, France, Italy, Germany and Spain. The patch, sold by U.S. drug company P&G, has failed to receive approval in the U.S.

Several members of the Food and Drug Administration's advisory committee said they were not satisfied with the number of women studied so far, the length of the studies and the modest benefits of the drug. No word on how many of those members were men (probably most of them). By a 14-3 vote, however, federal advisers said that benefit was "clinically meaningful."

Disclaimer from another blogger, here.

Labels:

0 Comments:

Post a Comment

Links to this post:

Create a Link

<< Home